Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ractigen Closes $30 Million Financing for RNAa Candidates

publication date: Jan 27, 2022

Ractigen Therapeutics, an RNAa company, closed a Series A+ financing totaling $30 million to bring its portfolio of 10 programs into clinical trials. RNAa is based on short duplex RNAs, known as small activating RNAs, which up-regulate targeted endogenous genes, increasing production of therapeutic proteins silenced in diseased cells. Reactigen will also scale-up its oligonucleotide manufacturing capabilities. One year ago, Ractigen completed an $18 million Series A round. The A+ round was led by SDIC Venture Capital. The company is located in the Industry Park of Life and Health Science of Rudong, Jiangsu Province. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital